The present work examined the potential of making use of ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant in addition palbociclib. ARV-825 was effective in both p53 wild-sort (WT) breast tumor cells As well as in cells lacking practical p53 both by yourself or in combin